Ensartinib is an oral tyrosine kinase inhibitor(TKI)for the treatment of anaplastic lymphoma kinase(ALK)positive non-small cell lung cancer(NSCLC)or NSCLC whose disease has worsened after treatment with the first-generation ALK-TKI inhibitor Crizotinib and cannot tolerate treatment.This review of PubMed and CNKI studies on the application of ensartinib in ALK-positive NSCLC found that Ensartinib can effectively prolong the progression-free survival of patients,showing better efficacy than Crizotinib in both systemic and intracranial diseases,with less toxic side effects and high tolerance in patients.Ensartinib may be more cost-effective than other inhibitors in Chinese patients with advanced ALK-TKI-positive NSCLC.
维普
万方数据